However, the recent PROSPECT-ALZ phase 2 clinical trial (NCT05063539) testing the OGA inhibitor, Ceperognastat (LY3372689), in early symptomatic AD individuals failed to meet primary and secondary clinical symptom improvement outcomes https://www.alzforum.org/news/conference-coverage/tau-modification-drugs-take-hit-negative-trial. Here, OGA is linked to Alzheimer disease.